25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance).

BACKGROUND Data from animal and cell-line models suggest that vitamin D metabolism plays an important role in pancreatic tumor behavior. Although vitamin D deficiency has been implicated in numerous cancers, the vitamin D status of patients with advanced pancreatic cancer and the effect of baseline vitamin D levels on survival are unknown. METHODS Participants in this correlative study (CALGB 151006) were enrolled in CALGB 80303, which was a randomized trial of patients with advanced pancreatic cancer that demonstrated no difference in overall survival (OS) among patients treated with gemcitabine plus placebo vs gemcitabine plus bevacizumab. We measured baseline serum 25-hydroxyvitamin D (25[OH]D) levels and examined associations between baseline 25(OH)D levels and progression-free survival and OS using the Cox rank score test. All statistical tests were two-sided. RESULTS Of 256 patients with available serum, the median 25(OH)D level was 21.7ng/mL (range 4 to 77). 44.5% of patients were vitamin D deficient (25[OH]D <20ng/mL), and 32.4% were insufficient (25[OH]D ≥20 and <30ng/mL). 25(OH)D levels were lower in black patients compared with white patients, and patients of other/undisclosed race (10.7 vs 22.4 vs 20.9ng/mL, P < .001). Baseline 25(OH)D levels were not associated with PFS (HR = 1.00, 95% CI = 0.99 to 1.01, P = .60) or OS (HR = 1.00, 95% CI = 0.99 to 1.01, P = .95). CONCLUSION Vitamin D deficiency was highly prevalent among patients with a new diagnosis of advanced pancreatic cancer. Black patients had statistically significantly lower 25(OH)D levels than white patients. In this cohort of patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy, baseline 25(OH)D levels were not associated with PFS or OS.

[1]  R. Kay.  The Analysis of Survival Data , 2012 .

[2]  W. Grant,et al.  Differences in vitamin D status may account for unexplained disparities in cancer survival rates between African and white Americans , 2012, Dermato-endocrinology.

[3]  Yusuke Nakamura,et al.  A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303 , 2011, Clinical Cancer Research.

[4]  L. Dogliotti,et al.  Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic review. , 2011, The oncologist.

[5]  J. Meyerhardt,et al.  Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Schilsky,et al.  Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Bikle.  Vitamin D: newly discovered actions require reconsideration of physiologic requirements , 2010, Trends in Endocrinology & Metabolism.

[8]  H. Hanwell,et al.  An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. , 2009, Clinical biochemistry.

[9]  S. Cremers,et al.  High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Karl Pearson F.R.S..  X. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling , 2009 .

[11]  Carlos A Camargo,et al.  Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. , 2009, Archives of internal medicine.

[12]  M. Holick,et al.  Vitamin D status: measurement, interpretation, and clinical application. , 2009, Annals of epidemiology.

[13]  K. Hornik,et al.  Unbiased Recursive Partitioning: A Conditional Inference Framework , 2006 .

[14]  W. Willett,et al.  Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. , 2006, The American journal of clinical nutrition.

[15]  A. Dalgleish,et al.  Investigation of the Mechanisms by Which EB1089 Abrogates Apoptosis Induced by 9-cis Retinoic Acid in Pancreatic Cancer Cells , 2006, Pancreas.

[16]  Kouros Owzar,et al.  A multiple testing procedure to associate gene expression levels with survival , 2005, Statistics in medicine.

[17]  D. Rao,et al.  Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. , 2004, Clinical biochemistry.

[18]  M. Willingham,et al.  Pancreatic cancer cells express 25-hydroxyvitamin D-1α-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3 , 2004 .

[19]  M. Hewison,et al.  Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. , 2004, The Journal of steroid biochemistry and molecular biology.

[20]  M. Hewison,et al.  Expression of 25-hydroxyvitamin D3-1α-hydroxylase in pancreatic islets , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[21]  B. Ohlsson,et al.  Vitamins A and D but not E and K decreased the cell number in human pancreatic cancer cell lines , 2004, Scandinavian journal of gastroenterology.

[22]  M. Höglund,et al.  Vitamin D Receptor Is Expressed in Pancreatic Cancer Cells and a Vitamin D3 Analogue Decreases Cell Number , 2003, Pancreatology.

[23]  G. Oades,et al.  Vitamin D receptor‐dependent antitumour effects of 1,25‐dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer , 2002, BJU international.

[24]  M. Cogswell,et al.  Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. , 2002, The American journal of clinical nutrition.

[25]  J. Bartek,et al.  Sensitivity to growth suppression by 1α,25-dihydroxyvitamin D3 among MCF-7 clones correlates with Vitamin D receptor protein induction , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  W. Grant.  An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet‐B radiation , 2002, Cancer.

[27]  C. Hansen,et al.  Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. , 2002, Endocrine-related cancer.

[28]  A. G. de Herreros,et al.  Vitamin D3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of β-catenin signaling , 2001, The Journal of cell biology.

[29]  A. Howie,et al.  Extrarenal Expression of 25-Hydroxyvitamin D3-1α-Hydroxylase1 , 2001 .

[30]  A. Dalgleish,et al.  Differential and antagonistic effects of 9- cis -retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro , 2000, British Journal of Cancer.

[31]  M. Gottardis,et al.  Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. , 1996, British Journal of Cancer.

[32]  T. Nikaido,et al.  Inhibitory effect of 220-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines. , 1996, Gastroenterology.

[33]  J. Adams,et al.  INCREASED SKIN PIGMENT REDUCES THE CAPACITY OF SKIN TO SYNTHESISE VITAMIN D3 , 1982, The Lancet.

[34]  Philip H. Ramsey.  Nonparametric Statistical Methods , 1974, Technometrics.

[35]  D. Wolfe,et al.  Nonparametric Statistical Methods. , 1974 .

[36]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .

[37]  W. Kruskal,et al.  Use of Ranks in One-Criterion Variance Analysis , 1952 .

[38]  K. Pearson.  On the Criterion that a Given System of Deviations from the Probable in the Case of a Correlated System of Variables is Such that it Can be Reasonably Supposed to have Arisen from Random Sampling , 1900 .

[39]  A. Dreher.  Modeling Survival Data Extending The Cox Model , 2016 .

[40]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[41]  Kartikkumar Jinjuvadia,et al.  Racial Disparities in Gastrointestinal Cancers-Related Mortality in the US Population , 2012, Digestive Diseases and Sciences.

[42]  D. Black,et al.  Serum 25-hydroxyvitamin D is unaffected by multiple freeze-thaw cycles. , 2005, Clinical chemistry.

[43]  P M Stewart,et al.  Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. , 2001, The Journal of clinical endocrinology and metabolism.

[44]  E. Gunter,et al.  Hypovitaminosis D in medical inpatients. , 1998, The New England journal of medicine.

[45]  L. Binderup,et al.  Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. , 1997, British Journal of Cancer.